Delving into the Latest Updates on 11C-NS-8880 with Synapse

INTRODUCTIONPositron emission tomography (PET) imaging of the norepinephrine transporter (NET) is still hindered by the availability of useful PET imaging probes. The present study describes the radiosynthesis and pre-clinical evaluation of a new compound, exo-3-(6-methoxypyridin-2-yloxy)-8-H-8-azabicyclo[3.2.1]octane (NS8880), targeting NET. NS8880 has an in vitro binding profile comparable to desipramine and is structurally not related to reboxetine.METHODSLabeling of NS8880 with [(11)C] was achieved by a non-conventional technique: substitution of pyridinyl fluorine with [(11)C]methanolate in a Boc-protected precursor. The isolated [(11)C]NS8880 was evaluated pre-clinically both in a pig model (PET scanning) and in a rat model (μPET scanning) and compared to (S,S)-[(11)C]-O-methylreboxetine ([(11)C]MeNER).RESULTSThe radiolabeling technique yielded [(11)C]NS8880 in low (<10%) but still useful yields with high purity. The PET in vivo evaluation in pig and rat revealed a rapid brain uptake of [(11)C]NS8880 and fast obtaining of equilibrium. Highest binding was observed in thalamic and hypothalamic regions. Pretreatment with desipramine efficiently reduced binding of [(11)C]NS8880.CONCLUSIONBased on the pre-clinical results obtained so far [(11)C]NS8880 displays promising properties for PET imaging of NET.

100 Deals associated with 11C-NS-8880

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alzheimer Disease	Preclinical	Sweden	DanPET AB	-
Neuroendocrine Tumors	Discovery	Denmark	NTG Nordic Transport Group A/S	01 Oct 2014
Neuroendocrine Tumors	Discovery	Denmark	Århus Universitetshospital	01 Oct 2014
Neuroendocrine Tumors	Discovery	Sweden	DanPET AB	01 Oct 2014